There was a time when Vaxart (NASDAQ:VXRT) was in sharp focus among investors after it seemed that it could revolutionize the COVID 19 vaccine space with its oral pill.
That saw the stock hit a high of $24.90 a share in February this year but since then it has been in a continued downward spiral and eventually tanked by around 70%. The biggest setback for the company came on February 3 when Vaxart revealed that its oral vaccine VXA Cov2-1 did not actually produce antibodies.
That being said, there are still plenty of investors who hold a certain degree of hope regarding the company’s vaccine and believe it’s a low-risk bet on a unique COVID 19 vaccine. That being said, it seems more like wishful thinking and recently there was another setback when the Phase 2 trial of the product was deferred to June. Hence, it looks that the party for Vaxart stock may be over.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.